Bill Langbein

/Bill Langbein

Evolus & Urovant: Similar Strategies, Opposite Reactions to Positive Catalysts

One of the strongest performing biopharmaceutical stocks this year is [...]

ADMA New Catalysts For 2019 – Two PDUFA decisions on immunodeficiency therapies

SUMMARY SanaCurrents assigns a pivotal sentiment the FDA will approve [...]

Verona (VRNA) Talks Up The Long View Following Phase II Setback

Verona Pharma (NASDAQ:VRNA) highlighted a surprising benefit from a lower [...]

Cara Therapeutics (CARA) Q1 2019 Catalyst: Phase III efficacy trial, KALM-2

SUMMARY Sana Currents assigns a pivotal sentiment that Cara Therapeutics [...]

ADMA Biologics Believes It Can Resolve CRL Issues Quickly, Spring Review Possible

Shares of ADMA Biologics [NASDAQ:ADMA]  fell more than 45% on [...]